10 Jan 2006 - Enzon Pharmaceuticals, Inc. announced that it is returning its rights to ATG-Fresenius S to Fresenius Biotech GmbH, a subsidiary of the health care company Fresenius AG. ATG-Fresenius S is a polyclonal antibody preparation used for T-lymphocyte suppression to prevent organ graft rejection in organ transplant patients. The companies are committed to working together to assure a smooth transition for the current ongoing clinical trial for ATG-Fresenius S.
Enzon's decision to return full rights to Fresenius Biotech was based on its ongoing efforts to redirect its research and development investments to projects strategically aligned with its business objectives, including an increasing focus on cancer and adjacent therapeutic areas.
 |
www.bionity.com/news/e/51314 |
|
 |
|
|
© Chemie.DE Information Service GmbH http://www.bionity.com/news/e/51314 |
Seydelstr. 28 · 10117 Berlin info@chemie.de · Tel: +49 (0)30 20 45 68 - 0 |